Dublin, July 25, 2025 (GLOBE NEWSWIRE) — The “U.S. Minimal Residual Disease Testing Market Size, Share & Trends Analysis Report By Technology (Flow Cytometry, PCR, NGS), By Cancer Type (Hematological Malignancy, Solid Tumors), By End Use, And Segment Forecasts, 2025 – 2033” report has been added to ResearchAndMarkets.com’s offering.
The U.S. minimal residual disease testing market was estimated at USD 873.66 million in 2024 and is projected to grow at a CAGR of 9.38% from 2025 and 2033, driven by the country’s rising cancer burden and the healthcare system’s growing emphasis on precision medicine.
According to recent projections, about 89,190 people in the U.S. will be diagnosed with lymphoma in 2024, encompassing both Hodgkin and non-Hodgkin types. An estimated 21,050 deaths are anticipated, with non-Hodgkin lymphoma being both more common and deadlier, especially in men. These alarming statistics underscore the urgent demand for highly sensitive, early detection tools like MRD testing. MRD testing enables physicians to detect trace levels of cancer cells that persist after treatment, even when patients appear to be in remission. This technology plays a vital role in identifying patients at high risk of relapses, guiding further therapy, and improving long-term outcomes.
The shift toward value-based care and personalized treatment plans has elevated MRD testing from an optional research tool to a mainstream clinical necessity. As cancer therapies become more targeted and adaptive, the demand for precise disease monitoring tools like MRD testing continues to grow. This trend is especially pronounced in hematologic malignancies, where MRD status is increasingly being used as a surrogate endpoint in clinical trials and real-world treatment protocols.
Recent years have witnessed rapid advancements in next-generation sequencing (NGS) and flow cytometry, making MRD detection more accurate, reproducible, and clinically actionable. FDA-cleared tests such as Adaptive Biotechnologies’ clonoSEQ for multiple myeloma, acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL) have set new benchmarks for test sensitivity and adoption. Similarly, Natera’s Signatera, a tumor-informed ctDNA-based MRD test, is gaining traction in solid tumor management, including colorectal, breast, and bladder cancers. These assays allow for longitudinal disease tracking, personalized treatment decisions, and the early detection of recurrence-often months before symptoms or imaging changes appear.
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 100 |
| Forecast Period | 2024 – 2033 |
| Estimated Market Value (USD) in 2024 | $873.66 Million |
| Forecasted Market Value (USD) by 2033 | $2020 Million |
| Compound Annual Growth Rate | 9.3% |
| Regions Covered | United States |
U.S. Minimal Residual Disease Testing Market Variables, Trends, & Scope
Market Segmentation and Scope
- Market Lineage Outlook
- Parent Market Outlook
- Related/Ancillary Market Outlook
Market Drivers Analysis
- Rising incidence and prevalence of hematological malignancies
- Technological advancements in diagnostic tools
- Integration with personalized medicines
Market Restraint Analysis
- High cost and limited accessibility of advanced MRD technologies
U.S. Minimal Residual Disease Testing Market Analysis Tools
- Industry Analysis – Porter’s
- PESTLE Analysis
Companies Featured
- Twist Bioscience
- Thermo Fisher Scientific, Inc
- Illumina, Inc.
- QIAGEN
- Adaptive Biotechnologies
- Natera, Inc.
- Guardant Health
- Foresight Diagnostics, Inc.
- NeoGenomics, Inc.
- F. Hoffmann-La Roche Ltd.
- SOPHiA GENETICS
U.S. Minimal Residual Disease Testing Market Report Segmentation
Technology Outlook (Revenue, USD Million, 2021 – 2033)
- Flow Cytometry
- Polymerase Chain Reaction (PCR)
- Next Generation Sequencing (NGS)
- Amplicon-based NGS
- Hybridization Capture-based NGS
- Others
- Others
Cancer Type Outlook (Revenue, USD Million, 2021 – 2033)
- Hematological Malignancy
- Leukemia
- Lymphoma
- Solid Tumors
End Use Outlook (Revenue, USD Million, 2021 – 2033)
- Hospitals and Specialty Clinics
- Diagnostic Laboratories
- Academic and Research Institutes
- Others
For more information about this report visit https://www.researchandmarkets.com/r/ymr7b6
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- U.S. Minimal Residual Disease Testing Market
